A new study published in Aging Cell has found that Ponce De Leon Health's (PDLH) Rejuvant, a delayed-release calcium alpha-ketoglutarate (CaAKG) and vitamin supplement, was the only product among 84 commonly used supplements, drugs and commercial compounds to achieve statistically significant reductions in biological age.
PDLH said in a statement released yesterday that the findings position Rejuvant as a frontrunner in the rapidly expanding longevity nutraceuticals market.
The research
The study — which was conducted independently of PDLH — analysed data from more than 4000 subjects using DNA methylation clocks to uniformly measure biological age.
Participants taking Rejuvant showed an average age residual of 1.8 years lower than their chronological age. In absolute terms, users were measured as 5.74 years biologically younger.
Biological age (BA) and its residual relative to chronological age are popularly used to quantify individual ageing.
Crucially, Rejuvant remained statistically significant after adjustment for age, sex, smoking status, health condition and other covariates.
Every other supplement tested, including all NAD+ precursors, fell short of statistical significance.
The results represent a significant challenge to several supplement categories with strong consumer followings.
Standard CaAKG or AKG supplements showed a benefit estimated at eight times smaller than Rejuvant's, while NAD+ precursors — including NMN and NR — demonstrated effects approximately nine times smaller.
Neither category achieved statistical significance.
Senior author Dr Brian Kennedy, Director of the Centre for Healthy Longevity at the National University of Singapore, described the findings as unique for their scale and comparative rigour.
"This is a unique study that compares the effects of 84 different common supplements in a larger population of generally healthy individuals actively measuring their biologic age."
"While a few supplements were significant for reducing biologic age, the biggest effects by far were associated with Rejuvant, whereby users were 5.74 years younger than their chronologic age."
"After correction for possible confounders, only Rejuvant produced a statistically significant effect."
These findings reinforce my belief that Rejuvant is effectively and meaningfully reducing biologic age.
Dr Nir Barzilai, President of the Academy of Geroscience and Professor of Medicine at the Albert Einstein School of Medicine, added: "While many nutraceuticals have generated more enthusiasm than meaningful geroscience-based evidence, Rejuvant has at least a plausible mechanism of action and supportive preclinical data."
In addition, post-marketing experience suggests a more reassuring profile for use, safety and user satisfaction than the sweeping claims made for many other supplements.
"In today's longevity marketplace, that may not be a gold standard — but it is about as close as one gets to an adult in the room."
The findings are likely to resonate across the nutraceutical industry.
Biological age testing via epigenetic clocks is increasingly adopted by consumers and practitioners as a primary health metric and a product demonstrating a statistically validated effect on this endpoint (particularly in a head-to-head comparison against dominant supplement categories) carries significant commercial and scientific weight.